Overview

Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium. This study also assessed the safety and tolerability of patiromer and the effects of patiromer on serum potassium in heart failure (HF) participants with chronic kidney disease (CKD).
Phase:
Phase 2
Details
Lead Sponsor:
Relypsa, Inc.
Treatments:
Spironolactone